Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
6.71
-0.03 (-0.44%)
Nov 21, 2024, 11:39 AM EST - Market open
Vir Biotechnology Employees
Vir Biotechnology had 587 employees as of December 31, 2023. The number of employees increased by 11 or 1.91% compared to the previous year.
Employees
587
Change (1Y)
11
Growth (1Y)
1.91%
Revenue / Employee
$133,932
Profits / Employee
-$908,593
Market Cap
924.12M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 587 | 11 | 1.91% |
| Dec 31, 2022 | 576 | 132 | 29.73% |
| Dec 31, 2021 | 444 | 117 | 35.78% |
| Dec 31, 2020 | 327 | 98 | 42.79% |
| Dec 31, 2019 | 229 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Brookdale Senior Living | 36,000 |
| Owens & Minor | 22,200 |
| AMN Healthcare Services | 3,585 |
| Phibro Animal Health | 1,940 |
| HealthStream | 1,092 |
| Weave Communications | 844 |
| Zymeworks | 278 |
| Cogent Biosciences | 164 |
VIR News
- 2 days ago - Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - Business Wire
- 2 days ago - Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - Business Wire
- 6 days ago - Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire
- 16 days ago - Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off - Seeking Alpha
- 20 days ago - Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Business Wire
- 4 weeks ago - Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 - Business Wire
- 5 weeks ago - Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024 - Business Wire